Log in

Cellmid Stock Price, News & Analysis (ASX:CDY)

A$0.20
0.00 (0.00 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
A$0.20
Now: A$0.20
A$0.20
50-Day Range
A$0.20
MA: A$0.22
A$0.25
52-Week Range
A$0.17
Now: A$0.20
A$0.38
Volume20,000 shs
Average VolumeN/A
Market Capitalization$16.30 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cellmid Limited, a life sciences company, develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers Midkine (MK) ELISA Kit, a cancer biomarker, and diagnostic and prognostic tool. It is also developing CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia. In addition, the company develops and sells over-the-counter products; and develops and markets a range of FGF5 inhibitor hair growth products under the evolis name. As of November 01, 2018, it operated 17 stores and through online, which offers the évolis professional products in the United States. Cellmid Limited is based in Sydney, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9221 6830

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.46 million
Cash FlowA$0.03 per share
Book ValueA$0.07 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$16.30 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CDY and its competitors with MarketBeat's FREE daily newsletter.


Cellmid (ASX:CDY) Frequently Asked Questions

What is Cellmid's stock symbol?

Cellmid trades on the ASX under the ticker symbol "CDY."

Has Cellmid been receiving favorable news coverage?

News stories about CDY stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cellmid earned a news impact score of -1.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Cellmid.

Who are some of Cellmid's key competitors?

Who are Cellmid's key executives?

Cellmid's management team includes the folowing people:
  • Ms. Maria Halasz, CEO, MD & Exec. Director
  • Mr. Koichiro Koike, Managing Director of Advangen Inc (Age 62)
  • Dr. Graham Robertson, Head of R&D
  • Mr. Lee Tamplin, Company Sec.

What is Cellmid's stock price today?

One share of CDY stock can currently be purchased for approximately A$0.20.

How big of a company is Cellmid?

Cellmid has a market capitalization of $16.30 million and generates $7.46 million in revenue each year. View Additional Information About Cellmid.

What is Cellmid's official website?

The official website for Cellmid is http://www.cellmid.com.au/.

How can I contact Cellmid?

The company can be reached via phone at 61 2 9221 6830.


MarketBeat Community Rating for Cellmid (ASX CDY)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  7 (Vote Outperform)
Underperform Votes:  9 (Vote Underperform)
Total Votes:  16
MarketBeat's community ratings are surveys of what our community members think about Cellmid and other stocks. Vote "Outperform" if you believe CDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel